Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Phase 1 Completed 9 enrolled University of Colorado, Denver

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in combination with cetuximab in patients with advanced head and neck cancer.

Timeline

Start: 2011-04
Primary completion: 2013-12
Completion: 2013-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	—	Intravenous
Subject	Patidegib	Small molecule	—	Oral

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Summary

Timeline

Drugs

Indications